NewAmsterdam Pharma announced that its CFO Ian Somaiya and EVP of Investor Relations Matthew Philippe will participate in a virtual fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026. The company is a late-stage biopharmaceutical firm developing obicetrapib, an oral CETP inhibitor for LDL-C lowering in cardiovascular disease patients, with EMA approval decisions expected in H2 2026.

NewAmsterdam Pharma reported Q2 2025 earnings with $19.1 million in revenue, exceeding consensus estimates. The company showed progress in clinical trials for obicetrapib, a cholesterol-lowering therapy, and maintained strong cash reserves while preparing for potential European market entry.

NewAmsterdam Pharma announced positive results from a pre-specified Alzheimer's disease biomarker analysis in its Phase 3 BROADWAY trial, showing statistically significant reductions in key biomarkers in both the full study population and in ApoE4 carriers. The findings support the potential of obicetrapib, a CETP inhibitor, to prevent Alzheimer's disease progression.

NewAmsterdam Pharma, a late-stage biopharmaceutical company, announced the grant of inducement share options and restricted stock units to new hires, including the new Chief People Officer. The grants are aimed at incentivizing and retaining key personnel.

NewAmsterdam Pharma, a late-stage biopharmaceutical company, announced the closing of a $479.0 million public offering of ordinary shares and pre-funded warrants. The net proceeds will be used to fund the development of the company's lead product, obicetrapib, an oral LDL-lowering therapy.

NewAmsterdam Pharma, a late-stage biopharmaceutical company, announced the pricing of a $416.5 million public offering of ordinary shares and pre-funded warrants. The proceeds will be used to advance the development of the company's lead product candidate, obicetrapib, for the treatment of cardiovascular disease.

NewAmsterdam Pharma, a late-stage biopharmaceutical company, announced the commencement of a $300 million public offering of its ordinary shares and pre-funded warrants. The proposed offering is subject to market conditions and is expected to provide additional funding for the company's development of oral, non-statin medicines for patients at risk of cardiovascular disease.

NewAmsterdam Pharma announced positive topline data from its Phase 3 BROADWAY trial evaluating obicetrapib, an oral, non-statin medicine for patients with elevated LDL-C. The trial met its primary endpoint, showing a statistically significant reduction in LDL-C compared to placebo, and also observed a 21% reduction in major adverse cardiovascular events.

NewAmsterdam Pharma, a late-stage biopharmaceutical company, announced the grant of 100,000 inducement share options to a new non-executive hire. The options have an exercise price of $17.29 per share and will vest over four years.

NewAmsterdam Pharma, a late-stage biopharmaceutical company, announced its participation in upcoming investor conferences, where the company's management will host meetings and participate in fireside chats to discuss its pipeline and progress.

NAARDEN, the Netherlands and MIAMI, June 07, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 90,000 of NewAmsterdam’s ordinary shares to five non-executive new hires. The share options were granted as an inducement material to the employees’ acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).

NAARDEN, the Netherlands and MIAMI, May 03, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 30,000 of NewAmsterdam’s ordinary shares to three non-executive new hires. The share options were granted as an inducement material to the employees’ acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).